Durata Therapeutics Initiates Enrollment in a Phase 3b Study of Dalvance in 1500 mg Single Dose
April 24, 2014 at 08:32 AM EDT
Durata Therapeutics, Inc. (Nasdaq: DRTX) today announced that it has initiated enrollment of a Phase 3b clinical trial to evaluate the ...